Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604734 | 0.86 | CA2 (0.35) | POLBMAPTKDM4EMEN1KMT2A | |
| SCHEMBL26491282 | 0.84 | ACHE (0.45) | CA2CA1ACHEBACE1MAPK1 | |
| SCHEMBL13604827 | 0.83 | CA2 (0.33) | POLBMAPTKDM4EMEN1KMT2A | |
| SCHEMBL13604804 | 0.80 | CA2 (0.35) | MAPTCA2CA1ACHEBACE1 | |
| SCHEMBL13611728 | 0.79 | ACE2 (0.40) | MAPTCA2CA1 | |
| SCHEMBL13611574 | 0.79 | ACE2 (0.40) | MAPTCA2CA1 | |
| SCHEMBL13611716 | 0.78 | ACHE (0.41) | CA2CA1ACHEBACE1MAPK1 | |
| SCHEMBL6781652 | 0.78 | HCAR2 (0.44) | MAPTACHEBACE1 | |
| SCHEMBL4509146 | 0.78 | HCAR2 (0.44) | MAPTACHEBACE1 | |
| SCHEMBL26624680 | 0.78 | HCAR2 (0.44) | MAPTACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | CBR3, XDH, NQO2 | POLB 3073/4885MAPT 4868/4885KDM4E 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.